Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly

Federico Gatto, Claudia Campana, Francesco Cocchiara, Giuliana Corica, Manuela Albertelli, Mara Boschetti, Gianluigi Zona, Diego Criminelli, Massimo Giusti, Diego Ferone

Research output: Contribution to journalReview articlepeer-review


Acromegaly is a rare chronic, systemic disorder caused by excessive growth hormone (GH) secretion from a somatotroph pituitary adenoma. GH hypersecretion leads to overproduction of insulin-like growth factor-1 (IGF-1), which contributes to the somatic overgrowth, physical disfigurement, onset of multiple systemic comorbidities, reduced quality of life (QoL) and premature mortality of uncontrolled patients. Somatostatin receptor ligands, dopamine agonists and a GH receptor antagonist are currently available for medical therapy of acromegaly. The main aim of treatment is biochemical normalisation, defined as age-normalised serum IGF-1 values and random GH levels <1.0 μg/L. However, there is an increasing evidence suggesting that achieving biochemical control does not always decrease the burden of disease-related comorbidities and/or improve patients’ QoL. This lack of correlation between biochemical and clinical control can be due to both disease duration (late diagnosis) or to the peculiarity of a given comorbidity. Herein we conducted ad hoc literature searches in order to find the most recent and relevant reports on biochemical and clinical disease control during medical treatment of acromegaly. Particularly, we analyse and describe the relationship between biochemical, as well as clinical disease control in patients with acromegaly receiving medical therapy, with a focus on comorbidities and QoL. In conclusion, we found that current literature data seem to indicate that clinical disease control (besides biochemical control), encompassing clinical signs and symptoms, comorbidities and QoL, emerge as a primary focus of acromegaly patient management.

Original languageEnglish
Pages (from-to)365-381
Number of pages22
JournalReviews in Endocrine and Metabolic Disorders
Issue number3
Publication statusPublished - Sep 20 2019


  • Acromegaly
  • Biochemical control
  • Clinical control
  • Comorbidities
  • Medical therapy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly'. Together they form a unique fingerprint.

Cite this